Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside.
Mehra
M R
MR
Department of Internal Medicine, Ochsner Medical Institutions, New Orleans, La 70121, USA.
Ventura
H O
HO
Smart
F W
FW
Stapleton
D D
DD
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000473:pathology; D003331:Coronary Vessels / Q000187:drug effects / Q000473:pathology; D016027:Heart Transplantation / Q000473:pathology*; D006801:Humans; D011183:Postoperative Complications / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers